Hemoglobin Detection Wavelength Selection for Temperature Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing HPLC methods face challenges in accurately measuring glycated hemoglobin concentrations due to variations in the ratios of oxyhemoglobin and deoxyhemoglobin, which are affected by environmental temperature changes, making precise measurements difficult.
Innovation Solution
Setting the measurement wavelength between 417 to 427 nm, preferably between 419 to 425 nm, or at wavelengths where the molecular extinction coefficients of oxyhemoglobin and deoxyhemoglobin agree, such as 520 to 526 nm or 583 to 589 nm, to ensure accurate measurement of glycated hemoglobin concentration regardless of the ratios of oxyhemoglobin and deoxyhemoglobin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Illumination intensity
If measurement is performed at 415 nm (maximum absorption wavelength of oxyhemoglobin), then sensitivity to oxyhemoglobin is maximized, but measurement precision deteriorates when environmental temperature varies because the ratio of oxyhemoglobin and deoxyhemoglobin changes
Solution Approach 1:
The patent changes the measurement wavelength parameter from 415 nm to a specific range (417-427 nm, preferably 419-425 nm) where the molecular extinction coefficients of oxyhemoglobin and deoxyhemoglobin are substantially equal. This parameter change resolves the contradiction by selecting a wavelength that provides sufficient absorption intensity while being independent of the oxyhemoglobin/deoxyhemoglobin ratio, thereby maintaining measurement precision across varying environmental temperatures.
2Temperature
If environmental temperature varies, then dissolved gas concentration in eluent changes, but measurement stability deteriorates because the ratio of oxyhemoglobin and deoxyhemoglobin varies
Solution Approach 1:
The patent changes the measurement wavelength to a range (417-427 nm, preferably 419-425 nm) where the molecular extinction coefficients of oxyhemoglobin and deoxyhemoglobin are substantially equal. This parameter change makes the measurement independent of temperature-induced variations in hemoglobin composition, thereby maintaining measurement stability and reliability across different environmental temperatures.
3Ease of operation
If measurement is performed at a fixed wavelength, then measurement simplicity is maintained, but adaptability to different environmental conditions deteriorates
Solution Approach 1:
The patent identifies a specific wavelength range (417-427 nm, preferably 419-425 nm) where the molecular extinction coefficients of oxyhemoglobin and deoxyhemoglobin are substantially equal. By setting the measurement wavelength within this range, the system maintains operational simplicity while achieving adaptability to different environmental conditions, as the measurement becomes independent of temperature-induced hemoglobin composition changes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise and stable measurement of glycated hemoglobin concentration, minimizing the impact of environmental temperature variations and maintaining accuracy across different ratios of oxyhemoglobin and deoxyhemoglobin.
Implementation Method 1
a biological component is analyzed by continuously measuring the absorbance of the eluent
Implementation Method 2
introduce the sample into an analytical column 91 to thereby adsorb the biological components to a filler of the analytical column 91
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a method and an apparatus that measure the concentration of glycated hemoglobin by an optical technique. A wavelength in which the molecular extinction coefficient of oxyhemoglobin agrees or substantially agrees with the molecular extinction coefficient of deoxyhemoglobin is adopted as a measurement wavelength. Preferably, the measurement wavelength is set at from 417 to 421 nm. In the present invention, the concentration of glycated hemoglobin is measured by making use of column chromatography and of using a sample prepared from red blood cells in blood.